M-1231

Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals

5 months ago

• The esophageal cancer market is expected to grow significantly, driven by increasing prevalence and the introduction of novel therapies. • In 2023, approximately 77,000 new cases of esophageal cancer were reported across seven major markets, with Japan having the highest number. • Recent FDA approval of TEVIMBRA (tislelizumab) as a monotherapy marks a significant advancement in treating unresectable or metastatic ESCC. • Emerging therapies like zanidatamab and bemarituzumab are expected to revolutionize the esophageal cancer market dynamics during the forecast period.

Sutro Biopharma and Merck Advance Novel Cytokine Derivative into Phase 1 for Solid Tumors

3 years ago

• Sutro Biopharma announces the dosing of the first patient in a Phase 1 study for a novel cytokine derivative therapeutic developed in collaboration with Merck. • The therapeutic is designed for the treatment of advanced or metastatic solid tumors, marking a significant step in the collaboration between the two companies. • Sutro Biopharma will receive a $10 million payment from Merck as a result of achieving this clinical milestone, per the 2018 agreement. • The collaboration leverages Sutro's XpressCF® and Xpress CF+® platforms for cytokine derivative development, with Merck holding exclusive worldwide rights to resulting therapeutic candidates.

Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals

Sutro Biopharma and Merck Advance Novel Cytokine Derivative into Phase 1 for Solid Tumors

Drug Development Updates